A drug originally discovered by researchers at UCL has been granted £1.3m to enable clinical studies for the treatment of Multiple Sclerosis.
The Late Stage Award was made as part of the £180 million Biomedical Catalyst programme which addresses the need for new and effective healthcare solutions for a growing and ageing UK population.
Clinical studies will be conducted by Canbex Therapeutics Ltd working in partnership with UCL and Queen Mary University London.
After the initial research at UCL, this project builds on work conducted with a Wellcome Trust Translational Award leveraging additional investment by UCL Business.
Among the projects winning funding are: the world’s first clinical trial of a stem cell based voice box transplant; an innovative low-cost implantable blood pump for advanced heart failure; gene therapy for a genetic visual disorder; and a new therapeutic approach to controlling the immune system in infectious disease.
